Phase II trial design with growth modulation index as the primary endpoint-Reference-Cited by-同舟云学术

Phase II trial design with growth modulation index as the primary endpoint

Published:2018-11-20 Issue:2 Volume:18 Page:212-222
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Wu Jianrong¹²^ORCID,Chen Li¹²,Wei Jing³,Weiss Heidi¹²,Miller Rachel W.²⁴,Villano John L.²⁵

Affiliation:

1. Division of Cancer Biostatistics University of Kentucky Lexington Kentucky

2. Markey Cancer Center University of Kentucky Lexington Kentucky

3. Department of Statistics University of Kentucky Lexington Kentucky

4. Department of Obstetrics and Gynecology University of Kentucky Lexington Kentucky

5. Department of Internal Medicine University of Kentucky Lexington Kentucky

Funder

National Cancer Institute

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.1916

Reference19 articles.

1. Genomic Alteration–Driven Clinical Trial Designs in Oncology

2. Cancer immunotherapy trials: leading a paradigm shift in drug development

3. The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

4. Issues in Using Progression-Free Survival When Evaluating Oncology Products

5. There are no bad anticancer agents, only bad clinical trial designs–Twenty‐first Richard and Hinda Rosenthal Foundation Award Lecture;Von Hoff DD;Clin Cancer Res,1998

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimating the distribution of ratio of paired event times in phase II oncology trials;Statistics in Medicine;2022-12-27

2. Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial;JCO Precision Oncology;2022-08

3. The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: Current and future perspectives;Gynecologic Oncology Reports;2022-08

4. Community-driven development of a modified progression-free survival ratio for precision oncology;ESMO Open;2019